OrbiMed Advisors LLC Reduces Stake in PMV Pharmaceuticals, Inc.

OrbiMed Advisors LLC and OrbiMed Capital GP V LLC have filed Amendment No. 3 to Schedule 13D, reporting a decrease in their beneficial ownership of PMV Pharmaceuticals, Inc. common stock by more than 1%. As of October 27, 2025, OrbiMed Private Investments V, LP (OPI V) holds 4,975,291 shares, representing approximately 9.4% of the outstanding shares. This decrease follows transactions where OPI V sold 500,000 shares on September 10, 2025, at $1.80 per share and 1,000,000 shares on October 23, 2025, at $1.52 per share. The Reporting Persons may continue to adjust their investment based on market conditions and other factors. The filing also references an Amended and Restated Investors' Rights Agreement, which includes demand registration rights, piggyback registration rights, and Form S-3 registration rights for OPI V.